Lavaca Capital’s Sage Therapeutics SAGE Stock Holding History

Lavaca Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-28	Closed	-$4K	–	299
2019 Q1	$4K	Hold	28	–	–	﹤0.01%	341
2018 Q4	$3K	Buy	+28	New	+$3.2K	﹤0.01%	320

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Lavaca Capital's SAGE Position: Q2 2019 in Review

Lavaca Capital sold out of Sage Therapeutics (SAGE) in Q2 2019, closing a stake of 28 shares — an estimated $4K sold.

Lavaca Capital first reported a position in SAGE in Q4 2018 and held it in 2 quarters. The position peaked at $4K in Q1 2019. 272 funds tracked by Wall St. Rank hold SAGE as of Q2 2019.

Lavaca Capital reported no remaining Sage Therapeutics position as of Q2 2019 after selling out during the quarter.
Lavaca Capital sold 28 Sage Therapeutics shares in Q2 2019, an estimated $4K.
Lavaca Capital first reported a position in Sage Therapeutics in Q4 2018 and held it in 2 quarters.
Lavaca Capital's Sage Therapeutics position peaked at $4K in Q1 2019.
272 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2019.

Based on Lavaca Capital's 13F filing for Q2 2019, filed 29 Jul 2019.